Table 2 Prevalence of Blindness and Visual Impairment (VI) in the Singapore Chinese Eye Study, Based on the United States Definition*.
From: Trends of Visual Impairment and Blindness in the Singapore Chinese Population over a Decade
Vision status | Age group, years | Based on Presenting Visual Acuity | Based on Best-Corrected Visual Acuity | ||||
|---|---|---|---|---|---|---|---|
All (N = 3,353) | Male (N = 1,662) | Female (N = 1,691) | All (N = 3,353) | Male (N = 1,662) | Female (N = 1,691) | ||
n, (%) | n, (%) | n, (%) | n, (%) | n, (%) | n, (%) | ||
Bilateral blindness | 40-49 | 1 (0.1) | 0 (0.0) | 1 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
50–59 | 5 (0.5) | 3 (0.6) | 2 (0.3) | 1 (0.1) | 1 (0.2) | 0 (0.0) | |
60–69 | 4 (0.4) | 1 (0.2) | 3 (0.7) | 2 (0.2) | 1 (0.2) | 1 (0.2) | |
70+ | 12 (1.9) | 4 (1.2) | 8 (2.7) | 5 (0.8) | 2 (0.6) | 3 (1.0) | |
Total | 22 (0.7) | 8 (0.5) | 14 (0.8) | 8 (0.2) | 4 (0.2) | 4 (0.2) | |
Age-standardised prevalence, % (95% CI) † | 0.6 (0.3–0.9) | 0.4 (0.2–0.9) | 0.8 (0.4–1.4) | 0.2 (0.1–0.4) | 0.2 (0.1–0.6) | 0.2 (0.1–0.6) | |
Bilateral VI^ | 40–49 | 62 (8.0) | 26 (7.5) | 36 (10.0) | 3 (0.4) | 1 (0.3) | 2 (0.6) |
50–59 | 125 (11.2) | 50 (9.9) | 75 (12.3) | 6 (0.6) | 1 (0.2) | 5 (0.8) | |
60–69 | 210 (23.4) | 95 (20.1) | 115 (27.0) | 29 (3.3) | 12 (2.6) | 17 (4.0) | |
70+ | 298 (47.1) | 153 (45.5) | 145 (49.0) | 112 (17.7) | 57 (17.0) | 55 (18.6) | |
Total | 695 (20.7) | 324 (19.5) | 371 (21.9) | 150 (4.5) | 71 (4.3) | 79 (4.7) | |
Age-standardised prevalence, % (95% CI) † | 17.7 (16.0–19.6) | 15.3 (13.1–18.0) | 20.1 (17.6–23.1) | 3.4 (2.8–4.4) | 2.7 (1.9–4.0) | 4.2 (3.0–5.8) | |
Unilateral blindness | 40–49 | 12 (1.7) | 6 (1.7) | 6 (1.7) | 5 (0.7) | 3 (0.9) | 2 (0.6) |
50–59 | 17 (1.5) | 9 (1.8) | 8 (1.3) | 11 (1.0) | 4 (0.8) | 7 (1.2) | |
60–69 | 25 (2.8) | 17 (3.6) | 8 (1.9) | 18 (2.0) | 12 (2.5) | 6 (1.4) | |
70+ | 21 (3.3) | 13 (3.9) | 8 (2.7) | 30 (4.8) | 17 (5.1) | 13 (4.4) | |
Total | 75 (2.2) | 45 (2.7) | 30 (1.8) | 64 (1.9) | 36 (2.2) | 28 (1.7) | |
Age-standardised prevalence, % (95% CI) † | 2.1 (1.6–2.7) | 2.4 (1.7–3.3) | 1.8 (1.2–2.6) | 1.6 (1.2–2.1) | 1.7 (1.1–2.4) | 1.5 (1.0–2.3) | |
Unilateral VI | 40–49 | 113 (15.9) | 58 (16.6) | 55 (15.2) | 16 (2.3) | 9 (2.6) | 7 (1.9) |
50–59 | 237 (21.3) | 104 (20.7) | 133 (21.9) | 39 (3.5) | 21 (4.2) | 18 (3.0) | |
60–69 | 247 (27.4) | 143 (30.2) | 104 (24.4) | 113 (12.6) | 61 (12.9) | 52 (12.2) | |
70+ | 157 (24.8) | 91 (27.1) | 66 (22.3) | 174 (27.5) | 86 (25.6) | 88 (29.7) | |
Total | 754 (22.5) | 396 (23.8) | 358 (21.2) | 342 (10.2) | 177 (10.6) | 165 (9.8) | |
Age-standardised prevalence, % (95% CI) † | 21.1 (19.5–22.8) | 21.8 (19.6–24.3) | 20.2 (18.0–22.5) | 8.2 (7.3–9.1) | 7.8 (6.7–9.2) | 8.6 (7.3–10.1) | |
